|
|
 Previous Article | Table of Contents | Next Article 
Failure of Immunologic Purging in Mantle Cell Lymphoma Assessed by Polymerase Chain Reaction Detection of Minimal Residual Disease
Niels S. Andersen,
John W. Donovan,
Joseph S. Borus,
Christina M. Poor,
Donna Neuberg,
Jon C. Aster,
Lee M. Nadler,
Arnold S. Freedman, and
John G. Gribben
From the Divisions of Hematologic Malignancies and Biostatistics, Dana-Farber Cancer Institute, Boston, MA; and the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
To assess the clinical significance of minimal residual disease (MRD) detection by polymerase chain reaction (PCR) we analyzed samples from 26 patients with mantle cell lymphoma (MCL) who had undergone bone marrow transplantation (BMT) at the Dana-Farber Cancer Institute. The BCL-1/IgH translocation and clonally rearranged Ig heavy chain genes (IgH) provided molecular markers for detection and follow-up of MRD by polymerase chain reaction (PCR) amplification in 19 of the 26 (73%) MCL patients studied. IgH gene sequencing analysis showed somatic mutations in MCL that are characteristic of an antigen driven process suggesting that, in MCL, the final malignant transformation occurs in a mature B cell. Of the 19 patients with a PCR amplifiable marker, 17 underwent autologous, 1 an allogeneic, and 1 a syngeneic bone marrow transplantation (BMT). All patients had PCR-detectable MRD in the bone marrow (BM) at the time of BMT, irrespective of any history of histological BM involvement. In contrast to other B-cell malignancies, we found that immunological purging with complement-mediated lysis eradicated PCR-detectable MCL in only two patients. Moreover reinfusion of MRD was associated with a poor outcome. More than half of the patients undergoing autologous BMT had relapsed by the time of restaging at 2 years after autologous BMT. In four MCL patients in whom no residual lymphoma was reinfused, including the allogeneic and the syngeneic BMT, only one patient relapsed. Persistence of MRD detection after BMT was also associated with a high probability of relapse, although one patient did not have PCR-detectable MRD in peripheral blood or BM before relapse at nodal sites. We conclude that PCR amplification of disease-specific markers is a feasible and sensitive method to assess MRD and its clinical significance in patients with MCL. Moreover, PCR amplification provides a tool to evaluate modifications of purging and stem cell collection procedures that may be required for the management of this otherwise incurable disease.
Blood, Vol. 90 No. 10 (November 15), 1997:
pp. 4212-4221
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. S. Andersen, L. B. Pedersen, A. Laurell, E. Elonen, A. Kolstad, A. M. Boesen, L. M. Pedersen, G. F. Lauritzsen, R. Ekanger, H. Nilsson-Ehle, et al.
Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma
J. Clin. Oncol.,
September 10, 2009;
27(26):
4365 - 4370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Devizzi, A. Guidetti, C. Tarella, M. Magni, P. Matteucci, E. Seregni, C. Chiesa, E. Bombardieri, M. Di Nicola, C. Carlo-Stella, et al.
High-Dose Yttrium-90-Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation
J. Clin. Oncol.,
November 10, 2008;
26(32):
5175 - 5182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Geisler, A. Kolstad, A. Laurell, N. S. Andersen, L. B. Pedersen, M. Jerkeman, M. Eriksson, M. Nordstrom, E. Kimby, A. M. Boesen, et al.
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Blood,
October 1, 2008;
112(7):
2687 - 2693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Arcaini, F. Montanari, E. P. Alessandrino, A. Tucci, E. Brusamolino, L. Gargantini, R. Cairoli, P. Bernasconi, F. Passamonti, M. Bonfichi, et al.
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Ann. Onc.,
July 1, 2008;
19(7):
1331 - 1335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bottcher, M. Ritgen, S. Buske, S. Gesk, W. Klapper, E. Hoster, W. Hiddemann, M. Unterhalt, M. Dreyling, R. Siebert, et al.
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations
Haematologica,
April 1, 2008;
93(4):
551 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Dreger, M. Rieger, B. Seyfarth, M. Hensel, M. Kneba, A. D. Ho, N. Schmitz, and C. Pott
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome
Haematologica,
January 1, 2007;
92(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Pott, C. Schrader, S. Gesk, L. Harder, M. Tiemann, T. Raff, M. Bruggemann, M. Ritgen, B. Gahn, M. Unterhalt, et al.
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
Blood,
March 15, 2006;
107(6):
2271 - 2278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Pennell, A. Woods, M. Reis, R. Buckstein, D. Spaner, K. Imrie, K. Hewitt, A. Boudreau, A. Seth, and N. L. Berinstein
Association of Clinical Status of Follicular Lymphoma Patients after Autologous Stem Cell Transplant and Quantitative Assessment of Lymphoma in Blood and Bone Marrow as Measured by SYBR Green I Polymerase Chain Reaction
J. Mol. Diagn.,
February 1, 2006;
8(1):
40 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, M. Ladetto, F. Zallio, M. Astolfi, E. Rizzo, S. Sametti, A. Cuttica, R. Rosato, L. Farina, M. Boccadoro, et al.
Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes
J. Clin. Oncol.,
April 15, 2004;
22(8):
1460 - 1468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mangel, H. A. Leitch, J. M. Connors, R. Buckstein, K. Imrie, D. Spaner, M. Crump, N. Pennell, A. Boudreau, and N. L. Berinstein
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
Ann. Onc.,
February 1, 2004;
15(2):
283 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Li, J. Zhou, D. Zuckerman, M. Rue, V. Dalton, C. Lyons, L. B. Silverman, S. E. Sallan, and J. G. Gribben
Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection
Blood,
December 15, 2003;
102(13):
4520 - 4526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Gianni, M. Magni, M. Martelli, M. Di Nicola, C. Carlo-Stella, S. Pilotti, A. Rambaldi, S. Cortelazzo, C. Patti, G. Parvis, et al.
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
Blood,
July 15, 2003;
102(2):
749 - 755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Orchard, R. Garand, Z. Davis, G. Babbage, S. Sahota, E. Matutes, D. Catovsky, P. W. Thomas, H. Avet-Loiseau, and D. Oscier
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease
Blood,
June 15, 2003;
101(12):
4975 - 4981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Walsh, M. Thorselius, A. Johnson, O. Soderberg, M. Jerkeman, E. Bjorck, I. Eriksson, U. Thunberg, O. Landgren, M. Ehinger, et al.
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma
Blood,
May 15, 2003;
101(10):
4047 - 4054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Boye, T. Elter, and A. Engert
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Ann. Onc.,
April 1, 2003;
14(4):
520 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ritgen, A. Lange, S. Stilgenbauer, H. Dohner, C. Bretscher, H. Bosse, A. Stuhr, M. Kneba, and P. Dreger
Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia
Blood,
March 1, 2003;
101(5):
2049 - 2053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Howard, J. G. Gribben, D. S. Neuberg, M. Grossbard, C. Poor, M. J. Janicek, and M. A. Shipp
Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival
J. Clin. Oncol.,
March 1, 2002;
20(5):
1288 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Suzuki, K. Takemura, M. Tsutsumi, S. Nakamura, N. Hamajima, and M. Seto
Detection of Cyclin D1 Overexpression by Real-Time Reverse-Transcriptase-Mediated Quantitative Polymerase Chain Reaction for the Diagnosis of Mantle Cell Lymphoma
Am. J. Pathol.,
August 1, 2001;
159(2):
425 - 429.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Welzel, T. Le, R. Marculescu, G. Mitterbauer, A. Chott, C. Pott, M. Kneba, M.-Q. Du, R. Kusec, J. Drach, et al.
Templated Nucleotide Addition and Immunoglobulin JH-Gene Utilization in t(11;14) Junctions: Implications for the Mechanism of Translocation and the Origin of Mantle Cell Lymphoma
Cancer Res.,
February 1, 2001;
61(4):
1629 - 1636.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. S. Andersen, J. K. Larsen, J. Christiansen, L. B. Pedersen, N. S. Christophersen, C. H. Geisler, and J. Jurlander
Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures
Blood,
September 15, 2000;
96(6):
2219 - 2225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Magni, M. Di Nicola, L. Devizzi, P. Matteucci, F. Lombardi, L. Gandola, F. Ravagnani, R. Giardini, G. Dastoli, C. Tarella, et al.
Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion
Blood,
August 1, 2000;
96(3):
864 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Donovan, M. Ladetto, G. Zou, D. Neuberg, C. Poor, D. Bowers, and J. G. Gribben
Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia
Blood,
April 15, 2000;
95(8):
2651 - 2658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yatabe, R. Suzuki, K. Tobinai, Y. Matsuno, R. Ichinohasama, M. Okamoto, M. Yamaguchi, J.-i. Tamaru, N. Uike, Y. Hashimoto, et al.
Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma
Blood,
April 1, 2000;
95(7):
2253 - 2261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Guinan, V. A. Boussiotis, D. Neuberg, L. L. Brennan, N. Hirano, L. M. Nadler, and J. G. Gribben
Transplantation of Anergic Histoincompatible Bone Marrow Allografts
N. Engl. J. Med.,
June 3, 1999;
340(22):
1704 - 1714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Hosler, R. O. Bash, X. Bai, V. Jain, and R. H. Scheuermann
Development and Validation of a Quantitative Polymerase Chain Reaction Assay to Evaluate Minimal Residual Disease for T-Cell Acute Lymphoblastic Leukemia and Follicular Lymphoma
Am. J. Pathol.,
April 1, 1999;
154(4):
1023 - 1035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
